Capital Fund Management (CFM)
BMRN icon

Capital Fund Management (CFM)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Fund Management (CFM)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$797K Sell
14,100
-30,500
-68% -$1.78M ﹤0.01% 1760
2025
Q4 		$2.65M Sell
44,600
-51,000
-53% -$2.78M 0.01% 1554
2025
Q3 		$5.18M Buy
95,600
+11,100
+13% +$635K 0.01% 1228
2025
Q2 		$4.64M Buy
84,500
+23,100
+38% +$1.36M 0.01% 1190
2025
Q1 		$4.34M Sell
61,400
-43,900
-42% -$2.95M 0.01% 1075
2024
Q4 		$6.92M Buy
105,300
+83,300
+379% +$5.58M 0.02% 930
2024
Q3 		$1.55M Buy
+22,000
New +$1.84M ﹤0.01% 1547
2021
Q2 		– Sell
-10,900
Closed -$823K – 1434
2021
Q1 		$823K Sell
10,900
-17,700
-62% -$1.45M 0.01% 1015
2020
Q4 		$2.51M Buy
+28,600
New +$2.27M 0.02% 712
2016
Q2 		– Sell
-4,800
Closed -$396K – 1532
2016
Q1 		$396K Buy
+4,800
New +$391K ﹤0.01% 1232
2015
Q4 		– Sell
-2,300
Closed -$242K – 1541
2015
Q3 		$242K Sell
2,300
-300
-12% -$40.1K ﹤0.01% 1277
2015
Q2 		$356K Buy
2,600
+100
+4% +$12.4K ﹤0.01% 1195
2015
Q1 		$312K Buy
+2,500
New +$265K ﹤0.01% 1213
2014
Q4 		– Sell
-17,900
Closed -$1.29M – 1580
2014
Q3 		$1.29M Buy
17,900
+2,900
+19% +$191K 0.01% 832
2014
Q2 		$933K Buy
+15,000
New +$906K 0.01% 991
2013
Q4 		– Sell
-41,000
Closed -$2.96M – 1651
2013
Q3 		$2.96M Buy
41,000
+20,900
+104% +$1.39M 0.04% 505
2013
Q2 		$1.12M Buy
+20,100
New +$1.25M 0.02% 771

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s BMRN Position: Q1 2026 in Review

Capital Fund Management (CFM) reduced its BioMarin Pharmaceuticals (BMRN) stake by 16% in Q1 2026, selling an estimated $2.06M and leaving 181,065 shares worth $10.2M. The position accounts for 0.05% of the portfolio, ranked #543.

Capital Fund Management (CFM) first reported a position in BMRN in Q2 2013 and has held it in 16 quarters since. The position peaked at $14.4M in Q3 2015. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Capital Fund Management (CFM) held 181,065 shares of BioMarin Pharmaceuticals worth $10.2M as of Q1 2026.
  • Capital Fund Management (CFM) sold 35,369 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $2.06M.
  • BioMarin Pharmaceuticals made up 0.05% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #543 holding.
  • Capital Fund Management (CFM) first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
  • Capital Fund Management (CFM)'s BioMarin Pharmaceuticals position peaked at $14.4M in Q3 2015.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.